Combined inhibition of complement and CD14 efficiently attenuated the inflammatory response induced by staphylococcus aureus in a human whole blood model

Journal of Immunology

Volumn 192, Issue 6, 2014, Pages 2857-2864

  Skjeflo, Espen W ^a,b   Christiansen, Dorte ^a   Espevik, Terje ^c   Nielsen, Erik W ^a,b   Mollnes, Tom E ^a,b,c,d,e  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD11B ANTIGEN; CD14 ANTIBODY; CD14 ANTIGEN; CDP 20; CELL ANTIBODY; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT INHIBITOR; COMPSTATIN; ECULIZUMAB; EOTAXIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOTEICHOIC ACID; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; TLR2 ANTIBODY; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BLOOD; COMPARATIVE EFFECTIVENESS; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOMETRY; DRUG EFFICACY; HUMAN; INFLAMMATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; STAPHYLOCOCCUS AUREUS;

ANTIGENS, CD14; COMPLEMENT C3; COMPLEMENT C5; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; RECEPTOR, ANAPHYLATOXIN C5A; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TEICHOIC ACIDS; TOLL-LIKE RECEPTOR 2; TREATMENT OUTCOME;

EID: 84897536026     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300755     Document Type: Article

References (53)

1. Cohen, J. 2002. The immunopathogenesis of sepsis. Nature 420: 885-891.
2. Hodgin, K. E., and M. Moss. 2008. The epidemiology of sepsis. Curr. Pharm. Des. 14: 1833-1839.
3. Williams, S. C. 2012. After Xigris, researchers look to new targets to combat sepsis. Nat. Med. 18: 1001.
4. Dellinger, R. P., M. M. Levy, J. M. Carlet, J. Bion, M. M. Parker, R. Jaeschke, K. Reinhart, D. C. Angus, C. Brun-Buisson, R. Beale, et al; International Surviving Sepsis Campaign Guidelines Committee; American Association of Critical-Care Nurses; American College of Chest Physicians; American College of Emergency Physicians; Canadian Critical Care Society; European Society of Clinical Microbiology and Infectious Diseases; European Society of Intensive Care Medicine; European Respiratory Society; International Sepsis Forum; Japanese Association for Acute Medicine; Japanese Society of Intensive Care Medicine; Society of Critical Care Medicine; Society of Hospital Medicine; Surgical Infection Society; World Federation of Societies of Intensive and Critical Care Medicine. 2008. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med. 36: 296-327.
5. Alberti, C., C. Brun-Buisson, H. Burchardi, C. Martin, S. Goodman, A. Artigas, A. Sicignano, M. Palazzo, R. Moreno, R. Boulmé, et al. 2002. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. 28: 108-121.
6. Finfer, S., R. Bellomo, J. Lipman, C. French, G. Dobb, and J. Myburgh. 2004. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 30: 589-596.
7. Martin, G. S., D. M. Mannino, S. Eaton, and M. Moss. 2003. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med. 348: 1546-1554.
8. Kengatharan, K. M., S. De Kimpe, C. Robson, S. J. Foster, and C. Thiemermann. 1998. Mechanism of gram-positive shock: identification of peptidoglycan and lipoteichoic acid moieties essential in the induction of nitric oxide synthase, shock, and multiple organ failure. J. Exp. Med. 188: 305-315.
9. Mattsson, E., T. Hartung, S. Morath, and A. Egesten. 2004. Highly purified lipoteichoic acid from Staphylococcus aureus induces procoagulant activity and tissue factor expression in human monocytes but is a weak inducer in whole blood: comparison with peptidoglycan. Infect. Immun. 72: 4322-4326.
10. Holst, B., A. C. Raby, J. E. Hall, and M. O. Labéta. 2012. Complement takes its Toll: an inflammatory crosstalk between Toll-like receptors and the receptors for the complement anaphylatoxin C5a. Anaesthesia 67: 60-64.
11. Walport, M. J. 2001. Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066.
12. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
13. Ward, P. A. 2004. The dark side of C5a in sepsis. Nat. Rev. Immunol. 4: 133-142.
14. Lappegård, K. T., D. Christiansen, A. Pharo, E. B. Thorgersen, B. C. Hellerud, J. Lindstad, E. W. Nielsen, G. Bergseth, D. Fadnes, T. G. Abrahamsen, et al. 2009. Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc. Natl. Acad. Sci. USA 106: 15861-15866.
15. Kawai, T., and S. Akira. 2009. The roles of TLRs, RLRs and NLRs in pathogen recognition. Int. Immunol. 21: 317-337.
16. Elson, G., I. Dunn-Siegrist, B. Daubeuf, and J. Pugin. 2007. Contribution of Tolllike receptors to the innate immune response to Gram-negative and Grampositive bacteria. Blood 109: 1574-1583.
17. Song, W. C. 2012. Crosstalk between complement and toll-like receptors. Toxicol. Pathol. 40: 174-182.
18. Wang, M., J. L. Krauss, H. Domon, K. B. Hosur, S. Liang, P. Magotti, M. Triantafilou, K. Triantafilou, J. D. Lambris, and G. Hajishengallis. 2010. Microbial hijacking of complement-toll-like receptor crosstalk. Sci. Signal. 3: ra11.
19. Hawlisch, H., and J. Kö hl. 2006. Complement and Toll-like receptors: key regulators of adaptive immune responses. Mol. Immunol. 43: 13-21.
20. Brekke, O.-L., D. Christiansen, H. Fure, A. Pharo, M. Fung, J. Riesenfeld, and T. E. Mollnes. 2008. Combined inhibition of complement and CD14 abolish E. coli-induced cytokine-, chemokine- and growth factor-synthesis in human whole blood. Mol. Immunol. 45: 3804-3813.
21. Lee, C. C., A. M. Avalos, and H. L. Ploegh. 2012. Accessory molecules for Tolllike receptors and their function. Nat. Rev. Immunol. 12: 168-179.
22. Fournier, B. 2012. The function of TLR2 during staphylococcal diseases. Front. Cell Infect. Microbiol. 2: 167.
23. Mollnes, T. E., D. Christiansen, O. L. Brekke, and T. Espevik. 2008. Hypothesis: combined inhibition of complement and CD14 as treatment regimen to attenuate the inflammatory response. Adv. Exp. Med. Biol. 632: 253-263.
24. Lien, E., T. J. Sellati, A. Yoshimura, T. H. Flo, G. Rawadi, R. W. Finberg, J. D. Carroll, T. Espevik, R. R. Ingalls, J. D. Radolf, and D. T. Golenbock. 1999. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem. 274: 33419-33425.
25. Yoshimura, A., E. Lien, R. R. Ingalls, E. Tuomanen, R. Dziarski, and D. Golenbock. 1999. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J. Immunol. 163: 1-5.
26. Brekke, O. L., B. C. Hellerud, D. Christiansen, H. Fure, A. Castellheim, E. W. Nielsen, A. Pharo, J. K. Lindstad, G. Bergseth, G. Leslie, et al. 2011. Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood. Mol. Immunol. 48: 2159-2169.
27. Wang, J. E., A. Warris, E. A. Ellingsen, P. F. Jørgensen, T. H. Flo, T. Espevik, R. Solberg, P. E. Verweij, and A. O. Aasen. 2001. Involvement of CD14 and tolllike receptors in activation of human monocytes by Aspergillus fumigatus hyphae. Infect. Immun. 69: 2402-2406.
28. Qu, H., D. Ricklin, H. Bai, H. Chen, E. S. Reis, M. Maciejewski, A. Tzekou, R. A. DeAngelis, R. R. Resuello, F. Lupu, et al. 2013. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology 218: 496-505.
29. Mastellos, D., J. C. Papadimitriou, S. Franchini, P. A. Tsonis, and J. D. Lambris. 2001. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit impaired liver regeneration. J. Immunol. 166: 2479-2486.
30. Mollnes, T. E., O.-L. Brekke, M. Fung, H. Fure, D. Christiansen, G. Bergseth, V. Videm, K. T. Lappegård, J. Kö hl, and J. D. Lambris. 2002. Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 100: 1869-1877.
31. Mollnes, T. E., T. Lea, S. S. Frøland, and M. Harboe. 1985. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 22: 197-202.
32. Mollnes, T. E., H. Redl, K. Høgåsen, A. Bengtsson, P. Garred, L. Speilberg, T. Lea, M. Oppermann, O. Götze, and G. Schlag. 1993. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 91: 295-300.
33. Opal, S. M., and J. Cohen. 1999. Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit. Care Med. 27: 1608-1616.
34. Beran, O., R. Potměšil, and M. Holub. 2011. Differences in Toll-like receptor expression and cytokine production after stimulation with heat-killed grampositive and gram-negative bacteria. Folia Microbiol. (Praha) 56: 138-142.
35. Günther, J., K. Esch, N. Poschadel, W. Petzl, H. Zerbe, S. Mitterhuemer, H. Blum, and H. M. Seyfert. 2011. Comparative kinetics of Escherichia coli- and Staphylococcus aureus-specific activation of key immune pathways in mammary epithelial cells demonstrates that S. aureus elicits a delayed response dominated by interleukin-6 (IL-6) but not by IL-1A or tumor necrosis factor alpha. Infect. Immun. 79: 695-707.
36. De Kimpe, S. J., M. Kengatharan, C. Thiemermann, and J. R. Vane. 1995. The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure. Proc. Natl. Acad. Sci. USA 92: 10359-10363.
37. Wang, J. E., P. F. Jørgensen, M. Almlö f, C. Thiemermann, S. J. Foster, A. O. Aasen, and R. Solberg. 2000. Peptidoglycan and lipoteichoic acid from Staphylococcus aureus induce tumor necrosis factor alpha, interleukin 6 (IL-6), and IL-10 production in both T cells and monocytes in a human whole blood model. Infect. Immun. 68: 3965-3970.
38. Ho, Y. C., S. C. Chang, S. R. Lin, and W. K. Wang. 2009. High levels of mecA DNA detected by a quantitative real-time PCR assay are associated with mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 47: 1443-1451.
39. Rose, W. E., J. C. Eickhoff, S. K. Shukla, M. Pantrangi, S. Rooijakkers, S. E. Cosgrove, V. Nizet, and G. Sakoulas. 2012. Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J. Infect. Dis. 206: 1604-1611.
40. Miedzobrodzki, J., T. Panz, P. M. Plłonka, K. Zajac, J. Dracz, K. Pytel, Lł. Mateuszuk, and S. Chlłopicki. 2008. Platelets augment respiratory burst in neutrophils activated by selected species of gram-positive or gram-negative bacteria. Folia Histochem. Cytobiol. 46: 383-388.
41. Ip, W. K., A. Sokolovska, G. M. Charriere, L. Boyer, S. Dejardin, M. P. Cappillino, L. M. Yantosca, K. Takahashi, K. J. Moore, A. Lacy-Hulbert, and L. M. Stuart. 2010. Phagocytosis and phagosome acidification are required for pathogen processing and MyD88-dependent responses to Staphylococcus aureus. J. Immunol. 184: 7071-7081.
42. Ginsburg, I. 2002. Role of lipoteichoic acid in infection and inflammation. Lancet Infect. Dis. 2: 171-179.
43. Schröder, N. W. J., S. Morath, C. Alexander, L. Hamann, T. Hartung, U. Zähringer, U. B. Göbel, J. R. Weber, and R. R. Schumann. 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide- binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J. Biol. Chem. 278: 15587-15594.
44. Kusunoki, T., E. Hailman, T. S. Juan, H. S. Lichenstein, and S. D. Wright. 1995. Molecules from Staphylococcus aureus that bind CD14 and stimulate innate immune responses. J. Exp. Med. 182: 1673-1682.
45. von Aulock, S., S. Morath, L. Hareng, S. Knapp, K. P. van Kessel, J. A. van Strijp, and T. Hartung. 2003. Lipoteichoic acid from Staphylococcus aureus is a potent stimulus for neutrophil recruitment. Immunobiology 208: 413-422.
46. Schmidt, R. R., C. M. Pedersen, Y. Qiao, and U. Zähringer. 2011. Chemical synthesis of bacterial lipoteichoic acids: an insight on its biological significance. Org. Biomol. Chem. 9: 2040-2052.
47. Spiller, S., G. Elson, R. Ferstl, S. Dreher, T. Mueller, M. Freudenberg, B. Daubeuf, H. Wagner, and C. J. Kirschning. 2008. TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J. Exp. Med. 205: 1747-1754.
48. Meng, G., M. Rutz, M. Schiemann, J. Metzger, A. Grabiec, R. Schwandner, P. B. Luppa, F. Ebel, D. H. Busch, S. Bauer, et al. 2004. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113: 1473-1481.
49. Parker, D., and A. Prince. 2012. Staphylococcus aureus induces type I IFN signaling in dendritic cells via TLR9. J. Immunol. 189: 4040-4046.
50. Baumann, C. L., I. M. Aspalter, O. Sharif, A. Pichlmair, S. Blüml, F. Grebien, M. Bruckner, P. Pasierbek, K. Aumayr, M. Planyavsky, et al. 2010. CD14 is a coreceptor of Toll-like receptors 7 and 9. J. Exp. Med. 207: 2689-2701.
51. Fournier, B., and D. J. Philpott. 2005. Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev. 18: 521-540.
52. Krisinger, M. J., V. Goebeler, Z. Lu, S. C. Meixner, T. Myles, E. L. Pryzdial, and E. M. Conway. 2012. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. Blood 120: 1717-1725.
53. Sprong, T., P. Brandtzaeg, M. Fung, A. M. Pharo, E. A. Høiby, T. E. Michaelsen, A. Aase, J. W. van der Meer, M. van Deuren, and T. E. Mollnes. 2003. Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis. Blood 102: 3702-3710.